지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
이용수
초록· 키워드
오류제보하기
Objective: This study was designed to compare pegfilgrastim and filgrastim in diffuse large B-cell lymphoma (DLBCL) patients treated with a rituximab with cyclophosphamide, hydroxydaunorubicin, oncovin, and prednisone (R-CHOP) regimen in terms of clinical efficacy and cost-effectiveness. Method: Clinical efficacy was measured by trough level of absolute neutrophil count (ANC), days of ANC under 50% of baseline value, days of ANC under 90% of baseline value, duration of ANC recovery to baseline value, days of ANC less than 0.5 × 109 cells/L, and difference of peak and trough level of ANC during 1 cycle of R-CHOP regimen. To evaluate cost-effectiveness, total prices of used filgrastim and pegfilgrastim within 1 cycle of R-CHOP were analyzed. Results: In terms of clinical efficacy, trough level of ANC and days to ANC recovery showed statistical significance. The median trough levels of ANC with administration of filgrastim and pegfilgrastim were 0.18 and 1.94 (p = 0.021), respectively, and the median durations of ANC recovery to baseline value were 5.5 days and 2 days (p = 0.023), respectively. For the median days of ANC under 50% of baseline value, days of ANC under 90% of baseline value, days of ANC less than 0.5 × 109 cells/L, and difference of peak and trough level of ANC during 1 cycle of R-CHOP, the pegfilgrastim group performed better than the filgrastim group. However the difference was not statistically significant. In terms of overall expense during 1 cycle of R-CHOP, pegfilgrastim is about 3.43 times more expensive than filgrastim. Conclusion: Pegfilgrastim is more efficient than filgrastim in terms of clinical efficacy. In terms of prices, pegfilgrastim is more expensive than filgrastim for patients, but it is more convenient in clinical use. Therefore, pegfilgrastim should be the preferred choice of G-CSF for neutropenic patients. Further comparative study of pegfilgrastim and filgrastim is needed.
목차
등록된 정보가 없습니다.
참고문헌 (18)
참고문헌 신청
/ / Common Terminology Criteria for Adverse Events (CTCAE) version 4.0
/ / Health Insurance Review & Assessment Service
Amgen / / NEUPOGEN (filgrastim) Prescribing Information
Author affiliations from The Non-Hodgkin's Lymphoma Classification Project / 1997 / A clinical evaluation of the International Lymphoma Study Group classification of non-Hodg
Balducci L. / 2007 / Elderly cancer patients receiving chemotherapy benefit from first-cycle pegfilgrastim / Oncologist 12 (12) : 1416 ~ 1424
/ / Health Insurance Review & Assessment Service
Amgen / / NEUPOGEN (filgrastim) Prescribing Information
Author affiliations from The Non-Hodgkin's Lymphoma Classification Project / 1997 / A clinical evaluation of the International Lymphoma Study Group classification of non-Hodg
Balducci L. / 2007 / Elderly cancer patients receiving chemotherapy benefit from first-cycle pegfilgrastim / Oncologist 12 (12) : 1416 ~ 1424
함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Absolute Neutrophil Count after the First Chemotherapy Cycle as a Surrogate Marker for Treatment Outcomes in Patients with Neuroblastoma
Cancer Research and Treatment
2022 .01
-
Antenatal Care Services and Incidence of Low Birth Weight: A Comparison of Demographic and Health Surveys in 4 ASEAN Countries
예방의학회지
2022 .11
-
Dose-Dense Rituximab-CHOP versus Standard Rituximab-CHOP in Newly Diagnosed Chinese Patients with Diffuse Large B-Cell Lymphoma: A Randomized, Multicenter, Open-Label Phase 3 Trial
Cancer Research and Treatment
2019 .01
-
Nitric oxide-releasing albumin nanoclusters facilitate healing of methicillin-resistant Staphylococcus aureus-infected cutaneous wounds
Journal of Pharmaceutical Investigation
2024 .01
-
Treatment results of radiotherapy following CHOP or R-CHOP in limited-stage head-and-neck diffuse large B-cell lymphoma: a single institutional experience
Radiation oncology journal : ROJ
2017 .01
-
Analysis of hematologic parameters of donors, patients, and granulocyte concentrates to predict successful granulocyte transfusion
Blood Research
2019 .01
-
Clinical Significance of Non-neutropenic Fever in the Management of Diffuse Large B-Cell Lymphoma Patients Treated with Rituximab-CHOP: Comparison with Febrile Neutropenia and Risk Factor Analysis
Cancer Research and Treatment
2015 .01
-
Which One is More Effective, Filgrastim or Lenograstim, During Febrile Neutropenia Attack in Hospitalized Patients with Solid Tumors?
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
복합화학요법을 받은 미만성 거대 B세포 림프종 환자의 호중구감소증 발생에 영향을 미치는 요인: 환자-대조군 연구
Asian Oncology Nursing
2022 .09
-
Phase III of Study of R-CHOP-21 vs R-CHOP-14 for Untreated Stage III and IV B-cell Non-Hodgkin's Lymphoma: a Report from Iran
Asian Pacific journal of cancer prevention : APJCP
2016 .01
-
Laboratory Markers Indicating Gastrointestinal Involvement of Henoch-Schönlein Purpura in Children
Pediatric Gastroenterology, Hepatology & Nutrition
2015 .01
-
A Case-Control Study on the Predictors of Neonatal Near-Miss: Implications for Public Health Policy and Practice
Neonatal medicine
2021 .08
-
Predictive Parameters of Febrile Neutropenia and Clinical Significance of G-CSF Receptor Signaling Pathway in the Development of Neutropenia during R-CHOP Chemotherapy with Prophylactic Pegfilgrastim in Patients with Diffuse Large B-Cell Lymphoma
Cancer Research and Treatment
2022 .10
-
조현병에 대한 클로자핀 단독요법과 비정형 항정신병제 병합요법 시 혈액학적 변동성 비교 : 후향적 6개월 추적관찰 연구
대한조현병학회지
2017 .10
-
Impact of rituximab and half-dose CHOP as primary therapy for untreated symptomatic Waldenström Macroglobulinemia: review of a combined regimen of rituximab with an alkylating agent
Blood Research
2018 .01
-
A Case of Cutaneous Leukocytoclastic Vasculitis Associated with Granulocyte Colony-Stimulating Factor: An Unusual Presentation
Annals of Dermatology
2020 .01
-
비호지킨림프종 환자의 발열성 호중구감소증에 대한 페그필그라스팀의 예방효과
한국임상약학회지
2015 .01
-
Pegfilgrastim for primary prophylaxis of febrile neutropenia in breast cancer patients undergoing TAC chemotherapy
Annals of Surgical Treatment and Research
2018 .05
-
Scientific Evidence Supporting Policy Change: A Study on Secondhand Smoke Exposure in Non-smoking Areas of PC Rooms in Korea
Cancer Research and Treatment
2016 .01
이 논문의 저자 정보
최근 본 자료
댓글(0)
0